Objective: To assess long-term weight loss efficacy and safety of pramlintide used at different dosing regimens and in conjunction with lifestyle intervention (LSI).
Research Design And Methods: In a 4-month, double-blind, placebo-controlled, dose-ranging study, 411 obese subjects were randomized to receive pramlintide (six arms: 120, 240, and 360 microg b.i.d. and t.i.d.) or placebo in conjunction with a structured LSI program geared toward weight loss. Of the 4-month evaluable subjects (n = 270), 77% opted to continue preexisting treatment during an 8-month single-blind extension (LSI geared toward weight maintenance).
Results: At month 4, mean weight loss from baseline in the pramlintide arms ranged from 3.8 +/- 0.7 to 6.1 +/- 0.8 kg (2.8 +/- 0.8 kg with placebo). By month 12, initial 4-month weight loss was regained in the placebo group but was maintained in all but the 120-microg b.i.d. group. Placebo-corrected weight loss with 120 microg t.i.d. and 360 microg b.i.d. averaged 3.2 +/- 1.2 kg (3.1 +/- 1.1% body wt) and 3.3 +/- 1.1 kg (3.1 +/- 1.0% body wt), respectively, at month 4 (both P < 0.01; 4-month evaluable n = 270) and 6.1 +/- 2.1 kg (5.6 +/- 2.1% body wt) and 7.2 +/- 2.3 kg (6.8 +/- 2.3% body wt), respectively, at month 12 (both P < 0.01; 12-month evaluable n = 146). At month 12, 40 and 43% of subjects treated with 120 microg t.i.d. and 360 microg b.i.d., respectively, achieved >or=10% weight loss (vs. 12% for placebo). Nausea, the most common adverse event with pramlintide in the 4-month study (9-29% pramlintide vs. 2% placebo), was generally mild to moderate and occurred in <10% of subjects during the extension.
Conclusions: When used over 12 months as an adjunct to LSI, pramlintide treatment, with low-dose three-times-daily or higher-dose two-times-daily regimens, helped obese subjects achieve greater initial weight loss and enhanced long-term maintenance of weight loss.
The thyroid is a rare site for finding tumor metastases. Renal, colorectal, pulmonary, and mammary origin are the most frequent primary neoplasms. Clinical suspicion, early diagnosis, and active surveillance are important during follow-up.
Purpose: Pre-operative eating disorders are well documented within the metabolic and bariatric surgery (MBS) population, yet subthreshold dieting attempts are less understood. The objectives of this study were to define and categorize patients' preoperative dieting attempts, and to determine how attempts are associated with postoperative outcomes, eating disorders, and demographics.
Materials And Methods: Three hundred twenty-one patients (81.
The current research focused on examining the effect of a coating made from Balangu seed mucilage (TSM-BM) and gelatin (Ge), with varying concentrations of dill essential oil (DEO) (0 %, 1 %, and 2 %) and zinc oxide nanoparticles (ZnO-np) (0 % and 0.5 %), on the quality characteristics of cherries stored at 4 °C over intervals of 0, 4, 7, 11, 18, and 25 days. The study noted that the application of this coating, particularly when combined with DEO and ZnO-np, significantly reduced the rate of changes in several parameters, including weight loss, firmness, titratable acidity, pH, total soluble solids, ascorbic acid, total anthocyanin content, total phenolic content, and antioxidant activity (p˂0.
Objectives: The study aimed to evaluate the hidden blood loss (HBL) and its possible risk factors in patients with lumbar disc herniation undergoing percutaneous endoscopic lumbar discectomy (PELD) via posterolateral approach.
Patients And Methods: The clinical data of 170 lumbar disc herniation patients (101 males, 69 females; mean age: 57.7±18.
Objectives: The study aimed to evaluate the hidden blood loss (HBL) and its possible risk factors in patients undergoing percutaneous endoscopic cervical discectomy (PECD) via posterior approach to better guide the management of perioperative anemia in patients.
Patients And Methods: The study retrospectively analyzed the clinical data of 60 patients (33 males, 27 females; mean age: 55.3±7.
